MedTrace Logo

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

NCT02483936 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2025-12-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Conditions

  • Arterial Hypertension

Interventions

DRUG

Olmesartan medoxomil 40mg + chlorthalidone 12,5mg

1 tablet a day

DRUG

Olmesartan medoxomil 40mg + chlorthalidone 25mg

1 tablet a day

DRUG

Olmesartan 40mg + Hydrochlorothiazide 12,5mg

1 tablet a day

DRUG

Olmesartan 40mg + Hydrochlorothiazide 25mg

1 tablet a day

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2025-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483936 on ClinicalTrials.gov